NeuroSense Therapeutics Ltd. (NRSN) Statistics & Valuation Metrics - Stocknear

NeuroSense Therapeutics L...

NASDAQ: NRSN · Real-Time Price · USD
1.17
0.01 (0.86%)
At close: Sep 09, 2025, 3:59 PM
1.15
-1.70%
Pre-market: Sep 10, 2025, 08:00 AM EDT

NeuroSense Therapeutics Statistics

Share Statistics

NeuroSense Therapeutics has 24.6M shares outstanding. The number of shares has increased by 23.2% in one year.

24.6M
23.2%
3.27%
0.84%
17.83M
26,039
6.92%

Short Selling Information

The latest short interest is 259.8K, so 1.04% of the outstanding shares have been sold short.

259.8K
1.04%
1.25%
1

Valuation Ratios

The PE ratio is -2.19 and the forward PE ratio is -5.8. NeuroSense Therapeutics's PEG ratio is 0.06.

-2.19
-5.8
0
13.4
8.64
-2.2
0.06
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for NeuroSense Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.03.

2.21
2.21
0.03
-0.01
-0.01
-31.84

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-600.59K
17
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by 0.86% in the last 52 weeks. The beta is 1.57, so NeuroSense Therapeutics's price volatility has been higher than the market average.

1.57
0.86%
1.54
1.31
43.42
376,282

Income Statement

n/a
-22K
-9.9M
-10.21M
-9.88M
-9.9M
-0.55
Full Income Statement

Balance Sheet

The company has 3.38M in cash and 73K in debt, giving a net cash position of 3.31M.

3.38M
73K
3.31M
-36.66M
4.58M
2.41M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.13M and capital expenditures -3K, giving a free cash flow of -10.14M.

-10.13M
-3K
-10.14M
-0.54
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

NRSN does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for NRSN is $14, which is 1096.6% higher than the current price. The consensus rating is "Hold".

$14
1096.6%
Hold
2
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

-8.41
2